Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors

Ezio Bettini 1, Stephen M. Stahl 2,3, Sara De Martin 4, Andrea Mattarei 4, Jacopo Sgrignani 5, Corrado Carignani 6, Selena Nola 7, Patrizia Locatelli 7, Marco Pappagallo 4,7, Charles E. Inturrisi 7, Francesco Bifari 8, Andrea Cavalli 5,9, Andrea Alimonti 10,11,12,13,14,15, Luca Pani 7,16,17, Maurizio Fava 18, Sergio Traversa 7, Franco Folli 19 and Paolo L. Manfredi 7,*

1 In Vitro Pharmacology Department, Aptuit, An Evotec Company, 37135 Verona, Italy
2 Department of Psychiatry, VAMC (SD), University of California, San Diego, CA 92093, USA
3 Neuroscience Education Institute, Carlsbad, CA 92008, USA
4 Department of Pharmaceutics and Pharmacological Sciences, University of Padua, 35122 Padua, Italy
5 Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana (USI), 6500 Bellinzona, Switzerland
6 Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
7 Relmada Therapeutics, Coral Gables, FL 33134, USA
8 Department of Medical Biotechnology and Translational Medicine, University of Milan, 20122 Milan, Italy
9 Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland
10 Veneto Institute of Molecular Medicine, 35129 Padua, Italy
11 Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Miami, Miami, FL 33136, USA
12 Department of Health Services and Technology, ETH Zurich, 8092 Zurich, Switzerland
13 The Institute of Oncology Research, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland
14 Department of Medicine, Zurich University, 8006 Zurich, Switzerland
15 Department of Medicine—DIMED, University of Padova, 35122 Padua, Italy
16 Department of Psychiatry—DIMED, University of Padua, 35122 Padua, Italy
17 Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy
18 Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
19 Department of Health Sciences, University of Milan, 20122 Milan, Italy

* Correspondence: pmanfredi@relmada.com; Tel.: +1-786-629-1376

Abstract: Excessive Ca\(^{2+}\) currents via N-methyl-D-aspartate receptors (NMDARs) have been implicated in many disorders. Uncompetitive NMDAR channel blockers are an emerging class of drugs in clinical use for major depressive disorder (MDD) and other neuropsychiatric diseases. The pharmacological characterization of uncompetitive NMDAR blockers in clinical use may improve our understanding of NMDAR function in physiology and pathology. REL-1017 (esmethadone-HCl), a novel uncompetitive NMDAR channel blocker in Phase 3 trials for the treatment of MDD, was characterized together with dextromethorphan, memantine, (±)-ketamine, and MK-801 in cell lines over-expressing NMDAR subtypes using fluorometric imaging plate reader (FLIPR), automated patch-clamp, and manual patch-clamp electrophysiology. In the absence of Mg\(^{2+}\), NMDAR subtypes NR1-2D were most sensitive to low, sub-µM glutamate concentrations in FLIPR experiments. FLIPR Ca\(^{2+}\) determination demonstrated low µM affinity of REL-1017 at NMDARs with minimal subtype preference. In automated and manual patch-clamp electrophysiological experiments, REL-1017 exhibited preference for the NR1-2D NMDAR subtype in the presence of 1 mM Mg\(^{2+}\) and 1 µM L-glutamate. Tau off and trapping characteristics were similar for (±)-ketamine and REL-1017. Results of radioligand binding assays in rat cortical neurons correlated with the estimated affinities obtained in FLIPR assays and in automated and manual patch-clamp assays. In silico studies of NMDARs in closed and open conformation indicate that REL-1017 has a higher preference for docking and undocking the open-channel conformation compared to ketamine. In conclusion, the pharmacological characteristics of REL-1017 at NMDARs, including relatively low affinity at the NMDAR, NR1-2D subtype preference in the presence of 1 mM Mg\(^{2+}\), tau off and degree of trapping...
similar to (±)-ketamine, and preferential docking and undocking of the open NMDAR, could all be important variables for understanding the rapid-onset antidepressant effects of REL-1017 without psychotomimetic side effects.

**Keywords:** REL-1017; esmethadone HCl; N-methyl-D-aspartate receptor (NMDAR); dextromethadone; d-methadone; ketamine; memantine; dextromethorphan; MK-801; major depressive disorder (MDD)

1. Introduction

N-methyl-D-aspartate receptors (NMDARs) are ionotropic receptors gated by two ligands, glycine (or D-serine) and glutamate, and by the electric potential of the cell membrane. At resting membrane potential, Mg$^{2+}$ is situated in the channel pore formed by the four NMDAR subunits. When NMDAR channels are coincidentally in the open structural conformation and free from Mg$^{2+}$, they allow tightly regulated, subtype-specific Ca$^{2+}$ influx. The co-occurrence of open conformation and Mg$^{2+}$ release can be elicited by excitatory synaptic transmission with presynaptic glutamate release. When glutamate binds to NMDARs, changing their conformation from closed to open, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs), also activated by glutamate, determine AMPAR-mediated membrane depolarization and Mg$^{2+}$ release from the NMDAR channel pore, allowing Ca$^{2+}$ influx. This phasic, time-controlled, subtype-specific Ca$^{2+}$ signaling via NMDARs determines downstream effects that modulate synapses, forming the basis of structural and functional memory [1,2]. Tonic NMDAR-mediated Ca$^{2+}$ currents at resting membrane potential also require the coincident opening of the NMDAR structural conformation and release of Mg$^{2+}$ from the channel pore. The physiological role of tonic NMDAR-mediated Ca$^{2+}$ currents is increasingly recognized [3,4]. Excessive tonic Ca$^{2+}$ influx mediated by NMDARs may impair the availability of synaptic proteins [3], interfering with stimulus-evoked memory formation induced by phasic NMDAR activation. NMDAR channel blockers reduce excessive tonic Ca$^{2+}$ influx mediated by NMDARs and restore synaptic protein availability, enabling neural plasticity elicited by action potential-mediated, phasic Ca$^{2+}$ influx in animal models of depressive-like behavior [5–9]. NMDAR heterotetramers are composed of two constitutively expressed glycine-binding NR1 subunits, necessary for membrane expression of the functional channel, and two regulatory glutamate-binding NR2 subunits, named 2A, 2B, 2C, and 2D, which differentially regulate Ca$^{2+}$ influx. NMDARs regulate Ca$^{2+}$ influx during phasic and tonic receptor activity. NMDARs containing the 3A and 3B subunits bind only glycine and not glutamate and are not blocked by Mg$^{2+}$ [10], and therefore they were not included in our study.

The uncompetitive NMDAR blockers memantine, esketamine, and the dextromethorphan-quinidine combination are approved by the U.S. Food and Drug Administration (FDA) to treat Alzheimer’s disease, treatment-resistant depression (TRD), and pseudobulbar affect (PBA), respectively. Differences in clinical effects and indications among uncompetitive NMDAR channel blockers appear to be linked to unique receptor-ligand kinetic properties [1,4,11]. Therefore, advances in characterization of the pharmacological properties of therapeutically effective and clinically tolerated uncompetitive NMDAR blockers at the different NMDAR channel subtypes may improve our understanding of NMDAR-related pathophysiology in different disease states, potentially expanding therapeutic options.

REL-1017 (esmethadone HCl; dextromethadone HCl), the d-isomer of racemic methadone, is a low-affinity, low-potency, uncompetitive NMDAR channel blocker, devoid of meaningful opioid agonist effects [12] with experimental evidence for producing brain-derived neurotrophic factor (BDNF) and target of rapamycin complex 1 (TORC1)-dependent antidepressant-like effects [9], similarly to ketamine [5]. In a double-blind, placebo-controlled Phase 2 trial in patients with major depressive disorder (MDD) and inadequate response to standard serotonergic antidepressants, the addition of REL-1017 showed rapid, robust, and sustained antidepressant effects without dissociative side ef-
fects [13]. Phase 3 trials of REL-1017 as adjunctive treatment and as monotherapy in patients with MDD are currently ongoing (ClinicalTrials.gov Identiﬁers: NCT04855747; NCT04688164; NCT05081167). In the context of this work, the current studies aim to characterize the properties of REL-1017 and other uncompetitive NMDAR blockers on cell lines over-expressing specific human heterodimeric NMDAR channel subtypes by fluorometric imaging plate reader (FLIPR) Ca\(^{2+}\) assay and by automated and manual patch-clamp electrophysiology. Additionally, we performed [Piperidyl-3,4-(N)]-(N-[1-[2-thienyl]cyclohexyl]-3,4-piperidine ([\(^{3}H\)]TCP) radioligand binding displacement studies with the same molecules in the cerebral cortex of Wistar rats. Finally, we performed in silico studies with REL-1017, esketamine, and arketamine on the four NMDAR 2A-D subtypes, in closed and open conformational states.

2. Results

2.1. REL1017 Is a Blocker at All NMDAR Subtypes in FLIPR Ca\(^{2+}\) Assay

The effect of REL-1017 and other known NMDAR uncompetitive channel blockers (dextromethorphan, (±)-ketamine, memantine, and MK-801) were studied on specific heterodimeric NMDAR subtypes stably over-expressed in Chinese hamster ovary (CHO) cells by measuring intracellular Ca\(^{2+}\) levels using a FLIPR assay, performed at saturating L-glutamate concentration and in the absence of Mg\(^{2+}\). L-glutamate was selected as the stimulus at 10 \(\mu\)M, a concentration able to elicit maximal Ca\(^{2+}\) influx in each cell line expressing heterodimeric NMDAR subtypes NR1-2A, NR1-2B, NR1-2C, and NR1-2D, respectively (Figure 1; Figure S1).

![Figure 1](image-url)

**Figure 1.** REL-1017 concentration-response curve (CRC) was performed in the presence of 10 \(\mu\)M L-glutamate and 10 \(\mu\)M glycine but in the absence of extracellular Mg\(^{2+}\) by fluorometric imaging plate reader (FLIPR) Ca\(^{2+}\) assay using Chinese hamster ovary (CHO) cell lines expressing the indicated heterodimeric N-methyl-D-aspartate receptors (NMDARs). REL-1017 caused a decrease in the increased intracellular Ca\(^{2+}\) elicited by 10 \(\mu\)M L-glutamate with estimated IC\(_{50}\) concentrations of 43 \(\mu\)M, 23 \(\mu\)M, 23 \(\mu\)M, and 68 \(\mu\)M for 2A-, 2B-, 2C-, and 2D-containing NMDARs, respectively. 100 \(\mu\)M REL-1017, the maximal tested concentration, reduced Ca\(^{2+}\) influx by 30%, 14%, 15%, and 47% of that evoked by 10 \(\mu\)M L-glutamate for NR1-2A, NR1-2B, NR1-2C, and NR1-2D subtypes, respectively. Fitting parameters for REL-1017 and other known NMDAR blockers, which were tested in identical conditions, are reported in Table 1. Data are mean ± standard error of the mean (SEM), \(n = 6\) per group, and were fitted using the four-parameter logistic equation with GraphPad Prism v8.0. RFU is relative fluorescence units.
Table 1. IC₅₀ values of REL-1017 and reference NMDAR blockers.

|       | NR1-2A | NR1-2B | NR1-2C | NR1-2D |
|-------|--------|--------|--------|--------|
|       | IC₅₀ (µM) | Slope | Min. (%) | IC₅₀ (µM) | Slope | Min. (%) | IC₅₀ (µM) | Slope | Min. (%) | IC₅₀ (µM) | Slope | Min. (%) |
| REL-1017 | 43     | −1.0   | 30      | 25      | −1.1   | 14      | 23      | −0.84  | 15      | 68      | −0.68  | 47     |
| (±)-Ketamine | 30   | −0.76  | 23      | 6.3     | −0.78  | 8       | 3.4     | −0.83  | 8       | 11      | −1.1   | 12     |
| Memantine | 34    | −0.82  | 29      | 10      | −0.86  | 11      | 3.6     | −0.82  | 13      | 7.3     | −0.88  | 18     |
| Dextromethorphan | 51  | −0.80  | 35      | 15      | −0.89  | 14      | 5.2     | −1.0   | 14      | 28      | −1.2   | 43     |
| MK-801  | 0.29   | −0.69  | 4       | 0.07    | −0.94  | 4       | 0.58    | −1.0   | 7       | 0.76    | −1.2   | 11     |

IC₅₀ values of five selected NMDAR channel blockers were obtained via FLIPR assay, as exemplified for REL-1017 in Figure 1. Fitting values were obtained for every heterodimeric NMDAR via logistic equation in GraphPad Prism v8.0. Slope is also reported in the table, as well as the minimal % Ca²⁺ influx measured in the presence of 100 µM blocker, the highest tested concentration. For example, 100 µM REL-1017 reduced Ca²⁺ influx elicited by 10 µM L-glutamate by 15% in the 2C-containing cell line.

Every test item was applied at 11 different concentrations, ranging from 100 µM to 1.7 nM. Estimated IC₅₀ values, Hill slopes, and minimal percentage Ca²⁺ recorded for every test item are reported in Table 1 and Figure S2.

The calculated IC₅₀ values of test items were in the expected range: MK-801 was the most potent compound against all NMDAR subtypes, while (±)-ketamine, memantine, and dextromethorphan showed intermediate potencies between MK-801 and REL-1017 (Table 1). MK-801 was more potent against NMDARs containing the 2B subunit, with a measured IC₅₀ value of 70 nM. In these experimental conditions (in the absence of Mg²⁺ and at saturating L-glutamate concentration), all compounds except MK-801 demonstrated a greater potency and calculated affinity on the NR1-2C subtype, with IC₅₀ values of 23 µM, 3.4 µM, 3.6 µM, and 5.2 µM for REL-1017, (±)-ketamine, memantine, and dextromethorphan, respectively.

Six different concentrations of REL-1017 and other test molecules (50 µM, 12.5 µM, 3.13 µM, 0.781 µM, 0.195 µM, and 0.049 µM) were assayed by FLIPR in the presence of increasing concentrations of L-glutamate to verify the presence of insurmountable NMDAR antagonism, as theoretically expected from uncompetitive channel blockers (Figure 2; Figure S3).

The logistic equation fitting parameters for all tested items are reported in Table S2a–e. Results with REL-1017, (±)-ketamine, memantine, dextromethorphan, and MK-801 confirmed an insurmountable profile in a FLIPR Ca²⁺ assay, as expected for uncompetitive blockers. The data for all compounds were fitted to an operational equation for allosteric modulators [14–16] to estimate Kᵥ and % affinity ratio for each test item (Table 2; Table S1).

Estimated Kᵥ values for five NMDAR channel blockers were obtained through FLIPR assay by L-glutamate CRCs, either alone or in the presence of six different concentrations of test item. Experiments were conducted for the various test items, as exemplified in Figure 2 for REL-1017. Operational equation for allosteric modulators was used to estimate Kᵥ for all tested molecules, using the formula described in the Section 4.

Table 2. Kᵥ and affinity ratio values of REL-1017 and reference NMDAR blockers.

|       | NR1-2A | NR1-2B | NR1-2C | NR1-2D |
|-------|--------|--------|--------|--------|
|       | Kᵥ (µM) | Affinity Ratio (%) | Kᵥ (µM) | Affinity Ratio (%) | Kᵥ (µM) | Affinity Ratio (%) | Kᵥ (µM) | Affinity Ratio (%) |
| REL-1017 | 8.9   | 51     | 6.1    | 74     | 4.5    | 100    | 7.8    | 58     |
| (±)-Ketamine | 4.3  | 11     | 1.1    | 42     | 0.46   | 100    | 1.4    | 33     |
| Memantine | 3.6   | 8      | 0.58   | 48     | 0.28   | 100    | 0.59   | 47     |
| Dextromethorphan | 9.6  | 13     | 1.9    | 63     | 1.2    | 100    | 6.7    | 18     |
| MK-801  | 0.11  | 44     | 0.048  | 100    | 0.14   | 34     | 0.15   | 32     |
The estimated equilibrium dissociation constant, $K_B$, was measured to be in the $\mu$M range for all tested molecules, except MK-801, which demonstrated a sub-$\mu$M $K_B$. MK-801 was able to reduce the effect of L-glutamate by more than 50% in all NMDAR subtypes beginning at 781 nM. The estimated $K_B$ for MK-801 was $\leq 150$ nM in all NMDAR subtypes. The % affinity ratio was computed from estimated affinities, which are the reciprocal of $K_B$ values, arbitrarily setting the highest affinity for each NMDAR subtype as 100%. From this analysis, MK-801 showed a preference (100% affinity ratio) for the NR1-2B subtype, while all remaining test items showed a preference for the NR1-2C subtype (Table 2). REL-1017 $K_B$ values were measured to be 8.9 $\mu$M, 6.1 $\mu$M, 4.5 $\mu$M, and 7.8 $\mu$M for NMDAR subtypes 2A, 2B, 2C, and 2D, respectively. REL-1017 $K_B$ values were higher than (+)-ketamine $K_B$ values with affinity ratios of 2.1, 5.5, 9.8, and 5.6 for 2A-, 2B-, 2C-, and 2D-containing receptors, respectively. Notably, the L-glutamate concentration-response curve (CRC) in this FLIPR assay showed preferential activation of the NR1-2D subtype than at lower L-glutamate concentrations (Table S2a).
2.2. REL-1017 Shows a Preference for NR1-2D Subtype Composition in the Presence of Extracellular Mg$^{2+}$

Under physiological conditions, the presence of extracellular Mg$^{2+}$ blocks the NMDAR channel pore at resting membrane potentials [1]. Since in FLIPR assays membrane potential cannot be controlled, NMDAR-dependent intracellular Ca$^{2+}$ changes cannot be properly measured at physiological Mg$^{2+}$ concentrations (1 mM), where most NMDAR channels at resting membrane potentials would be blocked. Hence, to better characterize the potential activity of REL-1017 in vivo, we examined its effect in automated whole-cell patch-clamp experiments in the presence of physiological concentrations of extracellular Mg$^{2+}$ (Figure 3; Figures S4–S6).

We first verified that 1 mM MgCl$_2$ was able to elicit a voltage-dependent blockade when NMDARs were activated by 10 $\mu$M L-glutamate and 10 $\mu$M glycine (Figure S7) and showed that voltage-dependent Mg$^{2+}$ block is more robust in NR1-2A and NR1-2B subtypes as compared to NR1-2C and NR1-2D, confirming results previously obtained by Kuner and Schoepfer [17]. The current recorded at $-60$ mV was normalized to a $-30$ mV current value, which was arbitrarily set to be the 100% value for each NMDAR subtype. The $-60$ mV current was only $24 \pm 2.4\%$ and $26 \pm 1.8\%$ (mean ± standard error of the mean [SEM], $n = 4$) for NR1-2A and NR1-2B subtypes, respectively, while it was $64 \pm 5.6\%$ and $55 \pm 1.8\%$ (mean ± SEM, $n = 4$) for NR1-2C and NR1-2D subtypes, respectively. 10 $\mu$M REL-1017 significantly reduced both 10 $\mu$M and 1 $\mu$M L-glutamate–elicited currents at all measured voltages between $-30$ mV and $-80$ mV with the NR1-2D subtype. 10 $\mu$M REL-1017 also significantly reduced 10 $\mu$M L-glutamate–elicited currents at all measured voltages between $-30$ mV and $-80$ mV in NR1-2A subtypes. However, 10 $\mu$M REL-1017 was inactive on 1 $\mu$M L-glutamate–activated NR1-2A, NR1-2B, and NR1-2C subtypes and on 10 $\mu$M L-glutamate–activated NR1-2C subtypes. When NR1-2B was activated by 10 $\mu$M L-glutamate, 10 $\mu$M REL-1017 significantly reduced the elicited current only at $-30$ mV, $-40$ mV, and $-50$ mV.

To evaluate REL-1017 activity on specific NMDAR subtypes in the presence of extracellular Mg$^{2+}$ (1 mM MgCl$_2$), a CRC was performed in a manual patch-clamp assay on NMDARs activated by sub-saturating 1 $\mu$M L-glutamate at a voltage of $-60$ mV (Table 3; Figure S8).

Table 3. IC$_{50}$ values of REL-1017 in presence of Mg$^{2+}$.

| REL-1017 IC$_{50}$ in 1 mM MgCl$_2$ | Hill Slope | Cell Number |
|----------------------------------------|------------|-------------|
| NR1-2A                                 | 63.1       | 1.06        | 2-8         |
| NR1-2B                                 | 41.7       | 1.17        | 2-7         |
| NR1-2C                                 | 28.4       | 1.49        | 2-8         |
| NR1-2D                                 | 13.5       | 1.42        | 3-7         |

Experiments were conducted in whole-cell patch-clamp electrophysiology at a holding potential of $-60$ mV. REL-1017 CRCs were obtained via whole-cell manual patch-clamp recordings in the presence of sub-saturating 1 $\mu$M L-glutamate, 10 $\mu$M glycine, and 1 mM MgCl$_2$. Every clamped cell was assessed with a single concentration of REL-1017, and the cell number range indicates the minimum and the maximum number of clamped cells per concentration for each NMDAR subunit-expressing cell type. REL-1017 was found to be approximately five-fold more potent in blocking NR1-2D subtypes compared to NR1-2A subtypes. Fittings parameters for REL-1017 were obtained from data shown in Figure S8 and analyzed with GraphPad Prism v8.0.

IC$_{50}$ values for REL-1017 were measured to be 63.1 $\mu$M, 41.7 $\mu$M, 28.4 $\mu$M, and 13.5 $\mu$M for NR1-2A, NR1-2B, NR1-2C, and NR1-2D subtypes, respectively, confirming the preference of REL-1017 in blocking NMDARs of the NR1-2D subunit composition at physiological Mg$^{2+}$ concentrations, as observed by automated patch-clamp using a single REL-1017 concentration (10 $\mu$M).
Figure 3. 10 µM REL-1017 differentially blocked heterodimeric NMDARs in the presence of extracellular 1 mM Mg\textsuperscript{2+}. REL-1017 showed a preference for NMDARs containing the 2D subunit, which is blocked in the presence of either 10 µM or 1 µM L-glutamate at −30 mV or more negative voltages. Data were obtained in automated patch-clamp platform. Every data point represents mean ± SEM (n = 4) of normalized current elicited by 10 mM L-glutamate at indicated voltage, measured during a hyperpolarizing ramp, in the absence (○) or presence (●) of 10 µM REL-1017. Statistical results of one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test also reported p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) and p < 0.0001 (****). Glu is glutamate.
2.3. REL-1017 and (±)-Ketamine Show Similar Degree of Trapping in NMDARs

We compared REL-1017 and (±)-ketamine onset and offset kinetics, as well as “trapping” properties, as these parameters might be relevant for their differential pharmacological effects [18]. With the exception of MK-801, the tested NMDAR blockers in clinical use (ketamine, memantine, and dextromethorphan) or with potential for clinical uses (REL-1017) all showed the lowest IC₅₀ and Kᵦ values in recombinant cells expressing the NR1-2C subtype in the FLIPR assay. Therefore, we selected the NR1-2C subtype for this study. Future trapping studies with the NR1-2D subtype may add to the NR1-2D data.

A whole-cell manual patch-clamp recording assay demonstrated that 10 µM REL-1017 resulted in a 75% reduction of NR1-2C–mediated current, while (±)-ketamine at 10 µM, 3 µM, 1 µM, and 0.3 µM produced 97%, 90%, 75%, and 44% inhibition, respectively, in the absence of extracellular Mg²⁺ (Figure 4; Figure S4).

**Figure 4.** Experiments were conducted using whole-cell patch-clamp electrophysiology at a −70 mV holding potential. Concentrations of (±)-ketamine able to inhibit 75% of the current elicited by 10 µM glutamate and glycine each were applied to a cell line expressing heterodimeric NR1-2C NMDARs to carry out kinetic studies. These experiments showed that 10 µM REL-1017 and 1 µM (±)-ketamine elicited similar current blockade of approximately 75%. Control current (100%) was induced by 10 µM L-glutamate and 10 µM glycine, respectively, and resulted in −594.2 ± 103.7 pA (mean ± SEM, n = 28). 10 µM REL-1017 and 10 µM, 3 µM, 1 µM, and 0.3 µM (±)-ketamine reduced L-glutamate/glycine–elicited current by 74.6 ± 1.9% (n = 12), 97.2 ± 0.3% (n = 3), 89.7 ± 0.6% (n = 3), 74.6 ± 2.2% (n = 3), and 44.2 ± 3.0% (n = 7), respectively.

Therefore, kinetic parameters of the two items were evaluated (Figure 5; Table 4; Table 5) at concentrations eliciting a similar effect (75% inhibition), i.e., 10 µM and 1 µM for REL-1017 and (±)-ketamine, respectively.
Figure 5. Sample traces of 10 µM REL-1017 and 1 µM (±)-ketamine onset and offset kinetics. Experiments were conducted by whole-cell patch-clamp electrophysiology at a −70 mV holding potential in NR1-2C-expressing CHO cells. A protocol was established to measure how fast REL-1017 blockade of NMDAR-mediated currents can be established (onset kinetic) and how fast this blockade can be removed (offset kinetic) by perfusion with a buffer containing the agonist L-glutamate but devoid of REL-1017. Test item application protocol diagram (top) and sample traces (bottom) of test item onset and offset kinetic experiments are shown with 10 µM REL-1017-treated cell (left) or 1 µM (±)-ketamine–treated cell (right). $I_0$, $I_1$, and $I_2$ were the currents measured at the end of the first 5 s of 10 µM/10 µM L-glutamate/glycine application, the 30-s co-application with test item, and the final 50-s co-agonists application, respectively. In this case, s is seconds.

Table 4. Onset kinetic parameters.

|                | Tau on (s) | $I_1$ (% Current) | Cell Number |
|----------------|------------|-------------------|-------------|
| 10 µM REL-1017 | 4.7 ± 0.21 | 20.4%             | 11          |
| 1 µM (±)-ketamine | 4.7 ± 0.14 | 28.7%             | 10          |
| 10 µM (±)-ketamine | 0.99 ± 0.05 | 3.6%             | 4           |

Experiments were conducted in whole-cell patch-clamp electrophysiology at a holding potential of −70 mV. Onset kinetic constant (tau on) of an NMDAR antagonist represents the time required for the test item to reach approximately 63.2% of its current blocking effect. Tau on (s) is reported as mean ± SEM, while $I_1$ is the % current measured at the end of test item addition and normalized with respect to $I_0$ current, the current value before test item addition, which is set equal to 100%. Data passing normality (Shapiro–Wilk) test were analyzed with one-way ANOVA followed by Tukey’s test. **** is $p < 0.0001$. s is seconds.

Table 5. Offset kinetic parameters.

|                | Tau off (s) | $I_2$ (% Current) | Cell Number |
|----------------|------------|-------------------|-------------|
| 10 µM REL-1017 | 17.7 ± 1.0 | 98.5%             | 11          |
| 1 µM (±)-ketamine | 15.2 ± 0.63 | 95.5%             | 10          |
| 10 µM (±)-ketamine | 17.2 ± 3.0 | 102.9%            | 4           |

Experiments were conducted in whole-cell patch-clamp electrophysiology at a holding potential of −70 mV. Offset kinetic constant (tau off) of an NMDAR antagonist represents the time required for the removal of approximately 63.2% of the current blocking effect of the test molecules, in continuous perfusion with a buffer containing the agonist L-glutamate but not the test item. Tau off (s) is reported as mean ± SEM, while $I_2$ (% current) is measured at the end of test item removal and normalized with respect to $I_0$ current, the current value before test item addition, which is set equal to 100%. Data passing normality (Shapiro–Wilk) test were analyzed with one-way ANOVA followed by Tukey’s test. Tau off values results were not significantly different. s is seconds.

10 µM REL-1017 onset and offset kinetic parameters (tau on and tau off) were measured at 4.7 ± 0.21 s and 17.7 ± 1.0 s (mean ± SEM, n = 11), respectively. 1 µM (±)-ketamine tau on and tau off were similar at 4.7 ± 0.14 s and 15.2 ± 0.63 s (mean ± SEM, n = 10) each. 10 µM (±)-ketamine tau on and tau off were 0.99 ± 0.05 s and 17.2 ± 3.0 s (mean ± SEM, n = 4), respectively, with a significantly lower tau on value as compared to 1 µM (±)-ketamine. This was expected, as tau on kinetics are concentration dependent.
When comparing equal concentrations at 10 μM (±)-ketamine and 10 μM REL-1017, the (±)-ketamine tau on value was significantly different from the tau on of REL-1017, indicating an approximately 10-fold higher potency, consistent with the FLIPR Kᵢ values at the same NR1-2C NMDAR subtype.

We employed a previously described electrophysiological protocol [18] to measure the degree of each compound “trapping” in NMDARs for 10 μM REL-1017 and 1 μM (±)-ketamine (Figure 6; Table 6).

**Figure 6.** Trapping experiments were conducted in whole-cell patch-clamp electrophysiology at −70 mV holding potential. Trapping experiments were designed to measure trapped block (Bᵣ) of 10 μM REL-1017 or 1 μM (±)-ketamine that is % ratio between residual block (Br) after extensive (85 s) cell wash with glycine alone and initial test item block (B). Test item application protocol diagram (top) and sample traces (bottom) of trapping experiments with 10 μM REL-1017-treated cell (left) or 1 μM (±)-ketamine-treated cell (right) are shown. I₁st and I₂nd were the peak current measured within 1 s after onset of the first and second 10 μM/10μM L-glutamate/glycine addition, respectively. Results from trapping experiments are reported in Table 6. s is seconds.

**Table 6.** Trapping parameters.

| B₁₀ M REL-1017 | B₁₀ M (±)-ketamine | Bᵣ | Cell Number |
|----------------|---------------------|----|-------------|
| 10 μM REL-1017 | 83.8 ± 1.2 ***      | 71.8 ± 1.1 *** | 85.9 ± 1.9 | 13 |
| 1 μM (±)-ketamine | 74.0 ± 1.2          | 64.1 ± 1.3 | 86.7 ± 1.8 | 11 |

Experiments were conducted in whole-cell patch-clamp electrophysiology at a holding potential of −70 mV. Trapped block (Bᵣ) results were similar for 10 μM REL-1017 and 1 μM (±)-ketamine, although their initial block (B) and residual block (Br) were significantly different. Experiments were carried out as exemplified in Figure 5. Table data are mean ± SEM. Data passing normality (Shapiro–Wilk) test were analyzed with two-tailed unpaired T test. **** is p < 0.0001; *** is p < 0.001.

The blockade caused by 10 μM REL-1017 and 1 μM (±)-ketamine was significantly different, with values of 84 ± 1% (mean ± SEM, n = 13) and 74 ± 1% (mean ± SEM, n = 11), respectively. However, after 120 s of washout without agonist present, there were no significant differences in trapping blockade between REL-1017 and (±)-ketamine, with values of 85.9 ± 1.9% (mean ± SEM, n = 13) and 86.7 ± 1.8% (mean ± SEM, n = 11), respectively. These findings are consistent with the measured off-rate kinetics, which were similar for the two compounds and are consistent with the known correlation between off-rate and degree of trapping.

### 2.4. Glutamate Receptor Radioactive Binding Assays in Rat Cortical Membranes

To evaluate the binding of MK-801, (±)-ketamine, memantine, dextromethorphan, and REL-1017 to the NMDAR, displacement binding assays were performed in rat cortical membranes using the [³H]TCP radioligand. The IC₅₀ and Kᵢ were measured to be 3.52–2.39 nM for MK-801, 0.55–0.37 μM for (±)-ketamine, 0.79–0.53 μM for memantine, 2.06–1.40 μM for dextromethorphan, and 6.21–4.21 μM for REL-1017. We also tested binding affinities...
for all test items at a 10 μM concentration at other NMDAR sites (glutamate, glycine, and polyamine), other ionotropic glutamate receptors (AMPARs and kainate receptors), and at metabotropic glutamate receptors. Results at these additional receptors at a 10 μM concentration were below the 50% cutoff for all tested compounds, confirming below threshold affinity for other NMDAR binding sites and other glutamate receptors.

2.5. Computational Modeling

Chou and colleagues [19] recently deposited the structure of NMDAR in its open and closed conformation in the Protein Data Bank (PDB). To understand the structure-activity relationship (SAR) of REL-1017, arketamine, and esketamine and their binding mode inside the channel pore, we performed computational docking calculations for the open and closed receptor conformations of each receptor subtype (Figure S9; Figure S10). Figure 7 shows the structure of the NR1-2D receptor (panel A) and the positioning of REL-1017, arketamine, and esketamine at the NR1-2D channel pore in the open (panels B, C, D) and closed (panel E, F, G) conformations.

Figure 7. Structure of NR1-2D with drug binding site highlighted by a black box (A). The binding of esmethadone (B, light blue), arketamine (C, magenta), and esketamine (D, purple) in open (B–D, PDB code 6WHT) and closed (E–G, PDB code 6WHS) conformational states of NR1-2D are shown.
Our calculations demonstrate that REL-1017 has a higher preference for binding the open-channel conformation compared to arketamine and esketamine, as shown by their difference in docking scores, confirmed at the four receptor subtypes (Table 7). Glide docking score was parametrized to reproduce binding free energies; therefore, a more negative value corresponds to a higher affinity for the protein target.

Table 7. Glide docking score.

| Ligands | NR1-2A | NR1-2B | NR1-2C | NR1-2D |
|---------|--------|--------|--------|--------|
|         | Template 6WHS | Template 6WHT | Template 6WHS | Template 6WHT | Template 6WHS | Template 6WHT |
| REL-1017 | −6.5 | −8.0 | −6.7 | −8.0 | −6.7 | −8.1 | −6.4 | −8.1 |
| MK-801  | −7.0 | −7.0 | −7.2 | −6.7 | −7.1 | −6.7 | −7.1 | −6.7 |
| Arketamine | −6.1 | −6.6 | −7.0 | −6.6 | −6.2 | −6.6 | −6.3 | −6.6 |
| Esketamine | −6.1 | −6.5 | −6.4 | −6.5 | −6.0 | −6.0 | −6.0 | −6.0 |

The Glide docking score (kcal/mol) of some of the investigated ligands at the NMDAR model of closed (6WHS) and open (6WHT) channel conformation.

The computational analyses shown in Figure 7 indicate that esketamine and arketamine bind the closed conformation of the receptor in a similar position, which is situated above the selectivity filter (delimited by the residue Asn615 for the four subunits). The binding of both REL-1017 and esketamine in the open conformation was deeper in the channel compared to the binding position observed for the closed conformation and was deeper for esketamine compared to REL-1017 (Figure 7; Figure S9; Figure S10). Overall, these data appear to support the hypothesis that REL-1017 may have a higher preference for docking the NMDAR channel in the open conformation and a higher propensity for undocking from the NMDAR channel in the open conformation when compared to arketamine and esketamine.

3. Discussion

NMDAR channel pores of NR1-2A-D subunit compositions are gated into their open configuration upon the binding of two molecules of glycine or D-serine to the agonist domain on each NR1 subunit and the concurrent binding of two L-glutamate molecules to the agonist domain on each NR2 subunit. During phasic channel activation, presynaptic glutamate release induces AMPAR-mediated membrane depolarization leading to the release of Mg$^{2+}$ from the NMDAR channel pore, initiating time-controlled, subtype-specific influx of Ca$^{2+}$. Stimulus-evoked, action potential-mediated Ca$^{2+}$ signaling through NMDARs directs cellular signaling cascades that modulate synapses, forming memory [1,2]. The physiological role of tonic Ca$^{2+}$ signaling has been related to local availability of synaptic proteins and neuronal maturation [1,3,4,6–8]. Well-regulated tonic Ca$^{2+}$ currents, which are graded by “spontaneous” NMDAR-mediated miniature excitatory postsynaptic currents (NMDAR-mEPSCs), may be essential to ensure availability of synaptic proteins necessary for neural plasticity elicited by stimulus-evoked postsynaptic currents (NMDAR-eEPSCs) [3,6–8]. Excessive tonic NMDAR-mediated Ca$^{2+}$ currents can be downregulated by uncompetitive NMDAR antagonists, such as ketamine and esmethadone, restoring neural plasticity and resolving depressive-like behavior in animal models [5–9] and in patients [13,20]. The uncompetitive NMDAR channel blocker dextromethorphan has also shown efficacy without psychotomimetic effects in a Phase 2 trial of patients with MDD [21].

In this study, we performed in vitro and in silico characterizations of REL-1017 and other clinically relevant uncompetitive NMDAR antagonists in CHO cells over-expressing NR1-2A, NR1-2B, NR1-2C, or NR1-2D subtypes, in rat cortical membranes, and in computational models. As demonstrated in FLIPR assays, low glutamate concentrations were most active on NR1-2D subtypes (Table S2a), in agreement with prior studies [22]. As expected, REL-1017 and the other tested uncompetitive antagonists were able to antagonize
NMDAR-mediated Ca\(^{2+}\) influx triggered by glutamate. In the absence of physiological Mg\(^{2+}\), REL-1017, dextromethorphan, memantine, and (+)-ketamine showed some degree of preference for NR1-2C subtypes, as shown by FLIPR assay. However, the subtype preference for REL-1017 was generally low.

In FLIPR assays, REL-1017 showed calculated affinity that was lower compared to the other tested compounds, in alignment with the results of the \(^{3}H\)TCP radioligand binding displacement study in the cerebral cortex of Wistar rats. FLIPR assays were conducted in the absence of Mg\(^{2+}\) to allow cytosolic measurements of NMDAR-dependent Ca\(^{2+}\) influx; however, Mg\(^{2+}\) is physiologically present at the synaptic sites. In the presence of physiological concentrations of Mg\(^{2+}\) at resting membrane potentials, persistent tonic Ca\(^{2+}\) currents are seen preferentially via NR1-2C and NR1-2D subtypes [1,17] due to their lower affinity for Mg\(^{2+}\) compared to NR1-2A and NR1-2B subtypes [23].

In automated and manual patch-clamp electrophysiological recordings, in the presence of physiological Mg\(^{2+}\) and low glutamate concentrations, REL-1017 preferentially blocked Ca\(^{2+}\) currents mediated by NR1-2D in a voltage-dependent manner. These results are consistent with earlier findings for memantine and (+)-ketamine [24]. Ca\(^{2+}\) signaling at resting membrane potential is distinct from stimulus-evoked, AMPAR-mediated, phasic activation [1,4,25]. Tonic Ca\(^{2+}\) currents via NR1-2C and NR1-2D subtypes constitute a physiological signaling pathway important for neuronal maturation and plasticity [3,4]. Excess ambient glutamate can cause pathological tonic hyperactivity of NR1-2D subtypes (Table S2a), the subtype preferentially targeted by REL-1017 at physiological Mg\(^{2+}\) concentrations.

When experiments are conducted in the presence of Mg\(^{2+}\), (+)-ketamine and memantine have also shown similar subtype preference [24]. Furthermore, REL-1017 is positively charged at a physiological pH [26], and therefore it is not surprising that its block of NMDARs is voltage dependent, similar to Mg\(^{2+}\), as seen in the automated (Figure S7) and manual patch experiments. The voltage-dependent antagonism exerted by REL-1017 may help to explain the lack of dissociative side effects: when membrane potential shifts toward positive, such as during AMPAR-mediated depolarization, the positively charged REL-1017 molecule is less likely to be docked at its binding site within the channel pore. The voltage-dependent block exerted by REL-1017 does not cause dissociative side effects [13], potentially because it does not interfere with phasic NMDAR-mediated Ca\(^{2+}\) signaling at activation membrane potential. Following the completion of a phasic activation, once the membrane repolarizes with negative intracellular potential, Mg\(^{4+}\) and REL-1017 may exert their tonic blockade at the channel pore at resting or near-resting membrane potentials (tonic channel blockade), causing their physiological and therapeutic effects, respectively.

NR1-2D subtypes have the highest affinity for glutamate (Table S2a), which makes these subtypes more likely to be in the open configuration due to the effect of ambient glutamate. NR1-2D subtypes have a relatively low affinity for Mg\(^{2+}\) and therefore the highest probability of being coincidentally in the open configuration and free from the Mg\(^{2+}\) block [17]. NMDARs require glutamate binding for the change into the open configuration and must be concurrently free from Mg\(^{2+}\) before allowing Ca\(^{2+}\) influx during phasic and tonic activity. NR1-2D subtypes remain open for several seconds rather than a few hundred milliseconds or less of other NMDAR subtypes [1]. This extended Ca\(^{2+}\) permeability time after activation may increase the probability for the docking of uncompetitive channel blockers, such as REL-1017, into the NR1-2D subtype channel pore. Therefore, in the presence of physiological Mg\(^{2+}\) concentrations, compared to other receptor subtypes, the NR1-2D subtype may be the preferential target for REL-1017 and other clinically tolerated uncompetitive channel blockers.

The IC\(_{50}\) values determined by radioligand binding assays in this study (3.52 nM for MK-801, 0.55 µM for (+)-ketamine, 0.79 µM for memantine, 2.06 µM for dextromethorphan, and 6.21 µM for REL-1017) may be informative for determining clinical tolerability, with a lower IC\(_{50}\) likely indicative of a higher probability of dissociative effects. However, other characteristics, such as trapping [11], may help explain clinically meaningful pharmacody-
namic differences among uncompetitive NMDAR blockers with similar NMDAR affinity. Low trapping is considered the reason for the lack of cognitive side effects of memantine, despite its relatively high NMDAR affinity [11]. This low trapping of memantine may also determine its lack of efficacy in the treatment of MDD [27], despite the relatively high (±)-ketamine-like affinity for NMDARs, which was confirmed in our radioligand displacement assay and FLIPR assay. The degree of trapping of REL-1017 was similar to (±)-ketamine in our experimental conditions. The relatively low NMDAR affinity of REL-1017, compared to the tested uncompetitive NMDAR channel blockers, and its relatively high (±)-ketamine-like trapping, could help to explain the absence of dissociative side effects and the robust, rapid, and sustained antidepressant effects [13]. The lack of neuropathological changes in cortical neurons of rats exposed to high doses of REL-1017 [28], in contrast with other uncompetitive NMDAR antagonists known to produce Olney’s lesions [28–32], may also be related to the relatively lower affinity of REL-1017 at the NMDAR, confirmed in our radioligand binding assays, FLIPR assays, and automated and manual patch assays.

Computational studies of ketamine were recently performed for the NR1-2A and NR1-2B subtypes [33]. In this study, we included the NR1-2C and NR1-2D subtypes in our computational analysis. Compared to NR1-2A and NR1-2B subtypes, NR1-2C and NR1-2D subtypes have a higher probability of being antagonized by uncompetitive NMDAR channel blockers at concentrations potentially therapeutic for MDD and other disorders [24]. Our studies suggest that binding of both REL-1017 and esketamine in the open conformation of NMDARs was deeper in the channel compared to the binding position for the closed conformation. Furthermore, the binding site was deeper in the channel for esketamine compared to REL-1017, suggesting a higher propensity of REL-1017 compared to esketamine to undock from the open conformation. These computational findings, which may also be related to the larger size of REL-1017 compared to esketamine, could also help to explain the lack of dissociative effects of REL-1017, in contrast with esketamine and racemic ketamine. The importance of trapping and voltage dependence for NMDAR blockers has been underscored by Bolshakov and colleagues [34].

Recent data for REL-1017, including clinical data [13,35], experimental preclinical data [9], and the present pharmacological characterization of NMDAR channel blockers, support the hypothesis that excessive Ca\(^{2+}\) signaling via tonically and pathologically hyperactive NR1-2D subtypes may in part drive MDD. NR1-2D is the same receptor subtype that is preferentially activated by ambient glutamate and preferentially targeted by REL-1017 and other clinically relevant uncompetitive channel blockers. We therefore hypothesize that, when excessive tonic Ca\(^{2+}\) influx is corrected by an uncompetitive channel blocker with NR1-2D preference, such as REL-1017, the resolution of MDD symptomatology [13] may result from normalization of synaptic proteins that allow normal neural plasticity, as has been demonstrated in experimental models of depressive-like behavior using ketamine and REL-1017 [5–9]. Kotermanski and Johnson [24] have demonstrated that uncompetitive NMDAR blockers such as ketamine and memantine may also have a preference for the NR1-2D channel subtype in the presence of physiological Mg\(^{2+}\) concentrations. Therefore, the hypothesized mechanism of action of REL-1017 in the treatment of MDD appears to be similar to the mechanisms hypothesized for ketamine in animal models [5–9] and in patients with MDD [36].

Importantly, the approximately 10-fold higher affinity of ketamine at NMDARs, confirmed in the current FLIPR, electrophysiological, and radioligand studies, narrows the safety window of ketamine. Although temporary dissociative effects occur in most patients treated with racemic ketamine and esketamine at doses currently used to treat MDD, the current consensus is that induction of dissociative effects is not necessary for the rapid antidepressant effects of ketamine [37,38]. The low affinity of REL-1017 for the NMDAR spares the block of phasic NMDAR activity, as evidenced by its lack of dissociative effects at therapeutic exposures [13,39]. Despite its low affinity, REL-1017 remains trapped in the NMDAR selectivity pore similarly to ketamine and is therefore able to reduce excessive tonic Ca\(^{2+}\) currents, with downstream effects that restore synaptic proteins [40] and exert
antidepressant-like effects in animal models [9], increase serum BDNF [35], and rapidly improve MDD in patients [13]. The importance of tonic blockade by uncompetitive NMDARs in determining synaptic protein availability, synaptic enhancement, and resolution of depressive-like behavior in animal models has been anticipated by other authors [5–8]. The importance of the NR1-2D subtype in the sustained antidepressant actions of arketamine, a less potent NMDAR blocker compared to esketamine, has been suggested by experimental work showing that the sustained antidepressant-like effects of arketamine are lost in NR1-2D subunit knockout mice [41].

The preferential activity for NR1-2D subtypes at resting membrane potential in the presence of physiological Mg\(^{2+}\) and the sensitivity of this NMDAR subtype to low-concentration glutamate may explain the downregulating effects of uncompetitive NMDAR channel blockers on tonic Ca\(^{2+}\) currents via preferential block of hyperactivated NR1-2D subtypes. In particular, the effects of uncompetitive NMDAR channel blockers at NR1-2D subtypes may be seen when pathologically elevated ambient glutamate induces a higher probability of the open configuration preferentially for the NR1-2D subtype, as shown in this report.

Future studies of REL-1017 blocking effects on NMDAR-mEPSCs in cortical brain slices may add informative data to these results.

4. Materials and Methods

4.1. Drugs and Reagents

All chemicals were of analytical grade. Dextromethorphan and (±)-ketamine were from Merck Sigma-Aldrich (Milan, Italy). Memantine and (+)-MK-801 were from Bio-Pharmaceutical/Tocris (Milan, Italy). REL-1017 (dextromethadone HCl) was from SpecGx (Webster Groves, MO, USA).

Cell culture consumables were from Gibco Life Technologies (Milan, Italy), including Dulbecco’s Modified Eagle Medium/F12 (DMEM/F12; Cat # 21331), heat-inactivated fetal bovine serum (FBS; Cat # 10500), penicillin-streptomycin (Cat # 15140), L-glutamine (Cat # 25030), MEM nonessential amino acids (NEAAs; Cat # 11140), basic fibroblast growth factor (bFGF; Cat # 11139), G418 (Cat # 10131), Zeocin™ (Cat # R250), and TrypLE™ enzyme (Cat # 12604). Hygromycin B (Cat # 10687) and Fluo-4 (F14202) were from Invitrogen (Waltham, MA, USA).

4.2. Cell Lines

CHO cell lines stably over-expressing heterodimeric NMDARs composed of human NR1 and 2 subunits were generated by Aptuit, an Evotec company (Verona, Italy). Cell line details are available at ExPASy Cellosaurus database. Research Resource Identifiers (RRIDs) are CVCL_B3TY, CVCL_B3TZ, CVCL_B3U0, and CVCL_B3U1 for CHO-hNR1-2A, CHO-hNR1-2B, CHO-hNR1-2C, and CHO-hNR1-2D, respectively. Protein accession numbers were NP_015566, NP_000824, NP_000825, NP_000826, and NP_000827 for NR1, 2A, 2B, 2C, and 2D, respectively. NP_015566 corresponds to the NR1-1a splice variant [42] lacking the N1 cassette but including C1 and C2 cassettes. The four different heterodimeric NMDARs studied were NR1-2A, NR1-2B, NR1-2C, and NR1-2D. Cell lines were cultured for a maximum of 75 passages.

Cells were grown at 37 °C, 5% CO\(_2\) in DMEM/F12, added with 10% FBS, 1% penicillin-streptomycin, 2 mM L-glutamine, 1% MEM-NEAA, 500 µM ketamine, and selected antibiotics. Selected antibiotics were 10 µg/mL blasticidin, 400 µg/mL G418, 400 µg/mL hygromycin B (except for NR1-2B-CHO), and 300 µg/mL Zeocin™ (for NR1-2B-CHO cells only).

4.3. FLIPR Assay

FLIPR assay allowed for indirect measurement of intracellular Ca\(^{2+}\) concentration by means of a Ca\(^{2+}\)-sensitive fluorescent dye (Fluo-4) using the FLIPR instrument (Molecular Devices, San Jose, CA, USA). For these assays, 40 mM stock solutions of the test items were prepared in 100% dimethyl sulfoxide (DMSO), while glutamate and glycine 4 mM stock solutions were prepared in water. 384-well compound plates containing 400 × concentrated
test item, glutamate, and glycine were prepared using Labcyte Echo acoustic dispensing system and stored at −20 °C until the day of the experiment. Then, 4 × assay plates were prepared by the addition of 30 μL/well of assay buffer in the presence of 0.5% (v/v) poloxamer 188 solution (Sigma-Aldrich code P5556) on experiment day.

Cells were plated in 384 black/clear bottom plates, at a density of 15,000/well, in the presence of 500 μM ketamine and 10 μg/mL tetracycline to induce receptor expression (except for NR1-2B-CHO cells, which showed NMDAR constitutive expression) and then kept at 30 °C in 5% CO₂ incubator for 24 h. Plated cells were preloaded for 1 h with 2 μM Fluo-4 Ca²⁺-sensitive dye in presence of 2.5 mM probenecid, an inhibitor of nonspecific anion transport, and 500 μM ketamine to avoid cytotoxicity and then washed with a three-cycle wash in assay buffer. This wash procedure removed all ketamine, as assessed by a consistent full response elicited in positive control wells of every plate by 10 μM glutamate plus 10 μM glycine. Assay buffer composition was 145 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 1 g/liter D-(+)-glucose, and 20 mM HEPES (pH was adjusted to 7.3 with NaOH). Intracellular Ca²⁺ level was monitored by FLIPR (excitation wavelength at 470–495 nm, emission wavelength at 515–575 nm) for 10 s before and 5 min after the addition of test items. All test items, including L-glutamate (when present) and glycine, were added simultaneously. Glycine 10 μM was always included in every test item addition.

In FLIPR CRC experiments, every test item was assessed at 11 final concentrations: 100 μM, 33 μM, 11 μM, 3.7 μM, 1.2 μM, 412 μM, 137 nM, 46 nM, 15 nM, 5.1 nM, and 1.7 nM. L-glutamate and glycine were both used at a 10 μM final concentration. In FLIPR mode of action experiments, every test item was assessed at six final concentrations: 50 μM, 12.5 μM, 3.13 μM, 0.781 μM, 0.195 μM, and 0.049 μM. L-glutamate was assessed at 11 final concentrations: 100 mM, 1 mM, 100 μM, 10 μM, 3.3 μM, 1.1 μM, 370 mM, 123 mM, 41 nM, 13.7 nM, and 4.6 nM. Glycine was kept at a constant concentration of 10 μM during experiments. Fluorescence was measured as the area under the curve (AUC) during the 5 min immediately after the addition of the test item. FLIPR data were normalized to intracellular Ca²⁺ levels in the presence of 10 μM L-glutamate and 10 μM glycine as 100%, while in the presence of assay buffer as 0% response.

### 4.4. Whole-Cell Automated Patch-Clamp Assay

QPatch HTX (Sophion Bioscience, Denmark) automated planar whole-cell patch-clamp platform was used to assess the effects of REL-1017 on L-glutamate–elicited current on heterodimeric NMDARs in the presence of physiological Mg²⁺. For QPatch experiments, cells were grown in T-flasks first at 37 °C, 5% CO₂ for 3 to 4 h, then at 30 °C, 5% CO₂ for 18 to 24 h in DMEM/F12 medium with added 500 μM ketamine and 10 μg/mL tetracycline (except for NR1-2B-CHO cells) without additional antibiotics. Cells were manually detached from the culture dish and automatically dispensed in QPatch wells with extracellular solution in the presence of 1 mM Mg²⁺ and 500 μM ketamine. Extracellular solution composition was 155 mM NaCl, 3 mM KCl, 1.5 mM CaCl₂, 1 mM MgCl₂, 10 mM HEPES, and 10 mM D-glucose, adjusted to pH 7.4 with NaOH. Intracellular solution composition was 80 mM CsF, 50 mM CsCl, 0.5 mM CaCl₂, 10 mM HEPES, and 11 mM EGTA, adjusted to pH 7.25 with CsOH.

Clamped cells were extensively washed in extracellular buffer solution to eliminate endogenous L-glutamate and ketamine, which had been previously added to block excitotoxicity. NMDAR-mediated currents elicited by L-glutamate in the presence of 10 μM glycine and 1 mM MgCl₂ were recorded at different voltages. Holding potential was −80 mV, and voltage protocol included a depolarizing 2-s step pulse to +60 mV to check the quality of the seal and cell NMDAR expression level, followed by a 2-s ramp-up to holding potential. L-glutamate 10 μM or 1 μM was added during the pulse to +60 mV and washed away at the end of the ramp (Figure S6). L-glutamate addition was repeated in two consecutive voltage protocols, and 10 μM REL-1017 was present during the second L-glutamate addition in the treated group but not in the control group. MgCl₂ 1 mM was present throughout the L-glutamate addition.
4.5. Whole-Cell Manual Patch-Clamp Assay

Cells were grown on poly-D-lysine coated glass coverslips for manual patch-clamp whole-cell recording. Intracellular solution composition was 80 mM CsF, 50 mM CsCl, 0.5 mM CaCl₂, 10 mM HEPES, and 11 mM EGTA, adjusted to pH 7.25 with CsOH. Extracellular solution composition for on-/off-rate and trapping assays was 155 mM NaCl, 3 mM KCl, 1.5 mM CaCl₂, 10 mM HEPES, and 10 mM D-glucose, adjusted to pH 7.4 with NaOH. Extracellular solution for REL-1017 CRC also contained 1 mM MgCl₂. Whole-cell recordings occurred at −70 mV fixed voltage equal to holding potential for onset and offset kinetic and trapping assays using NR1-2C-CHO cells. Whole-cell recordings occurred at −60 mV for REL-1017 CRCs.

The data capture and primary analysis were accomplished using HEKA Elektronik’s PATCHMASTER software (v2.53). Data were filtered at 1 kHz and sampled at 2 kHz. Rapid agonist or agonist-antagonist application was accomplished using a BioLogic RSC-160 perfusion device (BioLogic, Seyssinet-Pariset, France). The system consisted of a custom-made manifold of three tubes, whose tip was placed at around 100 μm from the patch-clamped cell under study.

4.6. NMDAR Binding Assay in Rat Brain Cortical Membranes

Multiple concentrations of (+)-MK-801, (±)-ketamine, memantine, dextromethorphan, and REL-1017 were tested in displacement binding assays in rat cortical membranes by Eurofins Panlabs Discovery Services Taiwan (Taipei City, Taiwan). The tritiated [³H]TCP ligand was selected for its ability to bind the pore of NMDARs (specific binding 94%, Kᵣ 8.40 nM, and Bₘₐₓ 0.78 pmol/mg).

Wistar rat cortical membranes were obtained as previously described [43]. A 6.3-mg aliquot was incubated with 4 nM [³H]TCP for 45 min at 25 °C. Nonspecific binding was defined by 1 μM dizocilpine ((+)-MK-801). Each tested compound was evaluated at the following concentrations: 1 μM, 3 μM, 10 μM, 30 μM, 100 μM, 3 nM, 10 nM, 30 nM, 100 nM, and 300 nM in 10 mM Tris-HCl, pH 7.4, as an incubation buffer. Membranes were filtered and washed, and the filters were then counted to determine [³H]TCP specifically bound, allowing us to calculate IC₅₀ and Kᵢ for each tested compound.

IC₅₀ values were determined by a nonlinear, least squares regression analysis using MathIQ™ (ID Business Solutions Ltd., UK). The Kᵢ values were calculated using the Cheng and Prusoff equation [44], using the observed IC₅₀ of the tested compound and the concentration of radioligand employed in the assay.

4.7. Additional Radioligand Displacement Binding Assays

(±)-Ketamine, memantine, dextromethorphan, and REL-1017 were also submitted to Eurofins Panlabs Discovery Services Taiwan for single-concentration (10 μM) binding assays for the following receptors under the following conditions:

Glutamate, AMPA. Source: Wistar rat cerebral cortex. Ligand: 5.0 nM [³H]AMPA. Nonspecific ligand: 1.0 mM L-glutamic acid. Incubation time/temp: 90 min/4 °C. Specific binding: 90%. Incubation buffer: 50 mM Tris-HCl, pH 7.4, 200 mM KSCN.

Glutamate, kainate. Source: Wistar rat brain cortex. Ligand: 6.0 nM [³H]kainic acid. Nonspecific ligand: 1.0 mM L-glutamic acid. Incubation time/temp: 2 h/4 °C. Specific binding: 80%. Incubation buffer: 50 mM Tris-HCl, pH 7.4.

Glutamate, metabotropic, mGlu2 human: Source: Human recombinant Chem-1 cells. Ligand: 2.0 nM [³H]LY341495. Nonspecific ligand: 5.0 μM LY-354740. Incubation time/temp: 60 min/25 °C. Specific binding: 90%. Incubation buffer: 10 mM KH₂PO₄, 100 mM KBr, pH 7.6 (pH adjusted with KOH).

Glutamate, metabotropic, mGlu5 human: Source: Human recombinant CHO-K1 cells. Ligand: 30 nM [³H]quisqualic acid. Nonspecific ligand: 1.0 mM L-glutamic acid. Incubation time/temp: 2 h/25 °C. Specific binding: 85%. Incubation buffer: 25 mM HEPES, 1 mM MgCl₂, 2.5 mM CaCl₂, pH 7.4.
Glutamate, NMDA, agonism: Source: Wistar rat cerebral cortex. Ligand: 2.0 nM \[^{3}H\]CGP-39653. Nonspecific ligand: 1.0 mM L-glutamic acid. Incubation time/temp: 20 min/4 °C. Specific binding: 90%. Incubation buffer: 50 mM Tris-HCl, pH 7.4.

Glutamate, NMDA, glycine: Source: Wistar rat cerebral cortex. Ligand: 0.33 nM \[^{3}H\]MDL 105,519. Nonspecific ligand: 10.0 µM MDL 105,519. Incubation time/temp: 30 min/4 °C. Specific binding: 85%. Incubation buffer: 50 mM HEPES, pH 7.7.

Glutamate, NMDA, polyamine: Source: Wistar rat cerebral cortex. Ligand: 2.0 nM \[^{3}H\]ifenprodil. Nonspecific ligand: 10.0 µM ifenprodil. Incubation time/temp: 2 h/4 °C. Specific binding: 80%. Incubation buffer: 50 mM Tris-HCl, pH 7.4.

Glycine, strychnine sensitive: Source: Wistar rat spinal cord. Ligand: 10.0 nM \[^{3}H\]strychnine. Nonspecific ligand: 1.0 mM glycine. Incubation time/temp: 10 min/4 °C. Specific binding: 77%. Incubation buffer: 50 mM KH\(_2\)PO\(_4\), 200 mM NaCl, pH 7.1.

For each assay, quantitation was performed by radioligand binding, and significance was considered when ≥50% of max stimulation or inhibition was attained.

4.8. Computational Model of Four NMDAR Subtypes in the Open and Closed Conformational States

Structural models were generated for the four NMDAR subtypes using the homology modeling pipeline and implemented the Schrödinger suite for molecular modeling, leaving all the options to their default values.

Amino acid sequences of the subunits were retrieved from UniProt (Q12879, Q13224, Q14957, and O15399 for 2A, 2B, 2C, and 2D, respectively). The structure of the NR1b-2B subtype from *Rattus norvegicus* recently solved by Chou and colleagues [19] in the open (PDB 6WHT) and closed (PDB 6WHS) conformation was used as a template. Finally, all generated models were optimized using the protein preparation wizard procedure implemented by the Schrödinger suite.

Ligand docking calculation was performed with Glide [45,46], centering the grid on the QRN site [33] (i.e., the asparagine residues that correspond to position 615 in the template structures) and using the standard precision (SP) mode. All ligand structures were prepared by LigPrep software. In the case of ketamine, docking calculations were performed on both enantiomers (arketamine and esketamine).

4.9. Operational Equation for \(K_B\) Estimation

The operational equation for allosteric modulators [14–16] was created in GraphPad Prism v8.0 software to estimate \(K_B\) and \(\alpha\) parameters for every test item with the assumption that, as a channel blocker, every test item would be able to produce a complete blockade of agonist response at sufficiently high concentration:

\[
Y = E_{MAX} \frac{\frac{τ[A]}{EC_{50}(\tau+1)}}{\left(\frac{τ[A]}{EC_{50}(\tau+1)}\right) + \left(\frac{\frac{τ[A]}{EC_{50}(\tau+1)}}{1 + a(B)K_B}\right) + \frac{B}{K_B} + 1}
\]

where \(Y\) is the % effect of L-glutamate, \([A]\) is the L-glutamate molar concentration; \(E_{MAX}\) is the maximal possible L-glutamate effect estimated from the four-parameter logistic equation; \(EC_{50}\) is the half maximal effective L-glutamate concentration estimated from the four-parameter logistic equation; \(τ\) is an arbitrary L-glutamate efficacy value at NMDAR set at \(τ = 100\); \([B]\) is the test item molar concentration; \(K_B\) is the estimated test item equilibrium dissociation constant; and \(\alpha\) is the estimated cooperativity term, which indicates the effect of the test item on the L-glutamate dissociation equilibrium constant for the receptor (i.e., \(\alpha\) is the estimated ratio between the L-glutamate equilibrium dissociation constant in the absence and in the presence of the test item, and it is expected to be \(0 < \alpha \leq 1\) for a negative allosteric modulator affecting the agonist equilibrium dissociation constant). Calculated \(\alpha\) values are reported in Table S1. Percent affinity ratio was computed from estimated affinities, which are the reciprocal of \(K_B\), and considering the highest affinity for an NMDAR subtype as 100%.
4.10. Onset and Offset Kinetic Calculation

At least \( n = 10 \) independent cells were analyzed. For each cell, the current in the presence of 10 \( \mu M \) glycine only was set as 0%, while the steady-state current induced after 5 s of 10 \( \mu M \) L-glutamate and 10 \( \mu M \) glycine application was set as 100% (Figures S4 and S5). The time constants of onset (\( \tau_{\text{on}} \), seconds) and offset (\( \tau_{\text{off}} \), seconds) of test item inhibition of glutamate-induced current were calculated using a first order exponential equation:

First order equation for test item onset:

\[
I(t) = I_1 + (I_0 - I_1) \times e^{-t/\tau_{\text{on}}}
\]

First order equation for test item offset:

\[
I(t) = I_1 + (I_2 - I_1) \times (1 - e^{-t/\tau_{\text{off}}})
\]

\( I(t) \) is the current at time \( t \). \( t \) is the time (seconds) after test item application or removal in the onset or offset equation, respectively. \( I_0 \) is the current after 5 s of 10 \( \mu M \) L-glutamate and 10 \( \mu M \) glycine application prior to test item application. \( I_1 \) is the current 30 s after application of the test item in the presence of 10 \( \mu M \) L-glutamate and 10 \( \mu M \) glycine. \( I_2 \) is the current 50 s after removal of the test item in the continuous presence of 10 \( \mu M \) L-glutamate and 10 \( \mu M \) glycine. \( \tau_{\text{on}} \) (tau on) is the time constant (seconds) of onset. \( \tau_{\text{off}} \) (tau off) is the time constant (seconds) of offset.

4.11. Trapping Calculation

Trapping was calculated as previously described [18]. Blocks of 10/10 \( \mu M \) L-glutamate/glycine–evoked currents were calculated according to the formula

\[
B = \left( \frac{I - IB}{I} \right) \times 100,
\]

where \( I \) was determined as the current value derived from a linear extrapolation to the end of the L-glutamate antagonist co-application, and \( IB \) was the current measured at the end of L-glutamate/blocker co-application.

The residual block of L-glutamate–evoked currents was calculated according to the formula

\[
BR = \left( \frac{I_{1st} - I_{2nd}}{I_{1st}} \right) \times 100
\]

(2), where \( I_{1st} \) was the maximal current measured 1 s after onset of the first L-glutamate exposure, and \( I_{2nd} \) was the maximal current measured 1 s after onset of the delayed second L-glutamate exposure following washout of the blocker from the bath.

The block trapped (BT), or the amount of block remaining at the beginning of the second L-glutamate application as a percent of the initial block produced at the end of the previous L-glutamate/antagonist co-application, was calculated according to the formula

\[
BT = \frac{BR}{B} \times 100
\]

(3), where \( B \) and \( BR \) were defined as above.

4.12. Statistical Analysis

The normality (Shapiro-Wilk) test was performed before any statistical analysis. Only data that passed the normality test (\( p > 0.05 \)) were considered for statistical analyses. Comparisons between groups were performed by Student’s t-test for unpaired data or one-way analysis of variance (ANOVA) followed by the Tukey’s post hoc multiple comparison test, when appropriate. In all the experiments, \( p < 0.05 \) was considered statistically significant.

5. Conclusions

The pharmacological characteristics of REL-1017 at the NMDAR, such as relatively low receptor affinity, NR1-2D subtype preference, ketamine-like trapping, and propensity for undocking the NMDAR in the open conformation, may help us understand its actions as a rapid-onset antidepressant devoid of psychotomimetic side effects [13]. Progress in pharmacological characterization of uncompetitive NMDAR channel blockers by in vitro and in silico techniques, in light of experimental \([3,5–9]\) and clinical results \([13,21,37]\) with the same molecules, can improve our understanding NMDAR function in physiology and pathology. Tonically excessive Ca\(^{2+}\) currents through NR1-2D NMDAR subtypes expressed by select neuronal populations may be central to the pathophysiology of MDD and potentially other disorders.
Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ph15080997/s1, Figure S1: L-glutamate concentration-response curve (CRC) was obtained to characterize the four cell lines expressing different heterodimeric human N-methyl-D-aspartate receptors (NMDARs) by calculating their L-glutamate EC50.; Figure S2: CRCs of REL-1017, (±)-ketamine, memantine, dextromethorphan, and MK-801 were performed in the presence of 10 µM L-glutamate and 10 µM glycine but in the absence of extracellular Mg2+ by FLIPR Ca2+ assay using Chinese hamster ovary (CHO) cell lines expressing the indicated heterodimeric NMDARs.; Figure S3: Sample FLIPR traces are shown in presence of vehicle ( ———), in the presence of 10 µM L-glutamate plus 10 µM glycine alone (——), or in presence of REL-1017 at different concentrations: 3.7 µM ( ——— ), 11 µM ( ——— ), 33 µM ( ——— ), and 100 µM ( ——— ) in the four different NMDAR cell lines expressing hGluN1/hGluN2A, hGluN1/hGluN2B, hGluN1/hGluN2C, and hGluN1/hGluN2D receptors. In this case, glu is glutamate; gly is glycine; Figure S4: Current values obtained from different electrophysiology experiments during the onset phase were normalized and averaged to derive tau on parameters reported in Table 4. Traces represent % mean ± standard error of current after addition of 10 µM REL-1017 (n = 11), 1 µM (±)-ketamine (n = 10), and 10 µM (±)-ketamine (n = 4), while internal lines are relative fittings. In this case, esm is esmethadone; ket is ketamine; Figure S5: Current values obtained from different experiments during the offset phase were normalized and averaged to derive tau off parameters reported in Table 5.; Figure S6: A special protocol was designed to discard cells not perfectly clamped. 1 or 10 µM L-glutamate was added in the presence of 10 µM glycine and 1 mM MgCl2 and in the absence or presence of 10 µM REL-1017 500 milliseconds after a depolarizing step pulse to +60 mV.; Figure S7: Automated cell clamp was used to verify the magnitude of 1 mM Mg2+ blockade at different voltages in cell lines expressing different heterodimeric NMDARs. NMDAR currents decreased at negative voltages in the presence of Mg2+ as the ion blocks the NMDAR pore at negative voltages.; Figure S8: Recordings occurred at −60 mV fixed voltage equal to holding potential.; Figure S9: Structures of the complexes between esmethadone (light blue, panels A, D, G, J), arketamine (magenta, panels B, E, H, K), and esketamine (purple, panels C, F, I, L) in NR1-N2C, NR1-N2A, NR1-N2B, and NR1-N2D in the closed conformation models (PDB code 6WHS); Figure S10: Structures of the complexes between esmethadone (light blue, panels A, D, G, J), arketamine (magenta, panels B, E, H, K), and esketamine (purple, panels C, F, I, L) in the open conformation NR1-N2C model (PDB code 6WHS); Table S1: Operational equation parameters for REL-1017 and reference NMDAR blockers; Table S2a–e: L-glutamate EC50 values with or without REL-1017 and reference NMDAR blockers.

Author Contributions: Conceptualization, E.B., S.M.S., S.D.M., A.M., M.P., C.E.I., A.C., A.A., L.P., M.F., S.T., F.F. and P.L.M.; data curation, E.B., S.M.D., A.M., J.S., C.C., S.N., P.L., F.B., F.F. and P.L.M.; formal analysis, E.B., S.D.M., A.M., J.S., C.C., S.N., P.L. and F.F.; funding acquisition, E.B., A.C. and S.T.; investigation, E.B., S.M.S., C.C. and P.L.M.; methodology, E.B., S.M.S., S.D.M., A.M., J.S., C.C., S.N., P.L., A.C. and P.L.M.; project administration, S.T., F.F. and P.L.M.; resources, P.L.M.; software, E.B., J.S., C.C., S.N., P.L. and A.C.; supervision, E.B., S.M.S., S.D.M., A.M., M.P., C.E.I., A.C., A.A., M.F., S.T., F.F. and P.L.M.; validation, E.B., S.M.S., S.D.M., A.M., J.S., C.C., S.N., M.P., C.E.I., F.B., A.C., A.A., M.F., F.F. and P.L.M.; visualization, E.B., S.M.S., J.S., C.C., S.N., P.L., F.B., A.C. and F.F.; writing—original draft, E.B., S.M.S., S.D.M., A.M., J.S., C.C., S.N., P.L., M.P., C.E.I., A.C., A.A., L.P., M.F., S.T., F.F. and P.L.M.; writing—review and editing, E.B., S.M.S., S.D.M., A.M., J.S., F.B., A.C., L.P., M.F., F.F. and P.L.M., E.B., S.M.S., S.D.M. and A.M. contributed equally to this manuscript. M.F., S.T.; F.F. and P.L.M. contributed equally to this manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Relmada Therapeutics (Study Number VDD9974) and performed by Aptuit: Contract Code ZNA76485, Test Facility, Aptuit (Verona) Srl, Via Fleming 4, 37135 Verona (Italy). Investigators funded by Relmada contributed the study design; collection, analysis, and interpretation of data; and writing of this report. Relmada supported the investigators’ decision to submit the article for publication.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is contained within the article and supplementary material.
Acknowledgments: Editorial support for the current manuscript was performed by Sarah A. Laredo, Maté Fischer, and Lauren Hummel, each of Metis Medical Media, supported by Relmada Therapeutics, Inc., and Richard Perry, supported by Relmada Therapeutics, Inc., according to Good Publication Practices (GPP3). All opinions, conclusions, and data interpretation lie with the authors.

Conflicts of Interest: This research was sponsored by Relmada Therapeutics, Inc. Drs. Inturrisi and Manfredi are inventors on patents related to REL-1017. Sergio Traversa is an employee of Relmada Therapeutics. Drs. Manfredi, Pappagallo, Inturrisi, Stahl, Folli, and Pani have received compensation by Relmada Therapeutics as consultants. Drs. Bettini, Cavalli, Sgrignani, Carignani, Locatelli, and Fava are employed or have received compensation from companies or institutions that received funding from Relmada Therapeutics. These data were presented at the 2021 Society of Biological Psychiatry (SOBP) Annual Meeting and at the 2021 Neuroscience Education Institute Congress.

References

1. Hansen, K.B.; Yi, F.; Perszyk, R.E.; Furukawa, H.; Wollmuth, L.P.; Gibb, A.J.; Traynelis, S.F. Structure, function, and allosteric modulation of NMDA receptors. J. Gen. Physiol. 2018, 150, 1081–1105. [CrossRef] [PubMed]
2. Nicoll, R.A. A Brief History of Long-Term Potentiation. Neuron 2017, 93, 281–290. [CrossRef]
3. Sutton, M.A.; Taylor, A.M.; Ito, H.T.; Pham, A.; Schuman, E.M. Postsynaptic decoding of neural activity: eEF2 as a biochemical sensor coupling miniature synaptic transmission to local protein synthesis. Neuron 2007, 55, 648–661. [CrossRef]
4. Hanson, E.; Armbruster, M.; Lau, L.A.; Sommer, M.E.; Klaft, Z.J.; Swanger, S.A.; Traynelis, S.F.; Moss, S.J.; Noubary, F.; Chadchankar, J.; et al. Tonic Activation of GluN2C/GluN2D-Containing NMDA Receptors by Adjacent Glutamate Facilitates Cortical Interneuron Maturation. J. Neurosci. 2019, 39, 3611–3626. [CrossRef]
5. Li, N.; Lee, B.; Liu, R.J.; Banasr, M.; Dwyer, J.M.; Iwata, M.; Li, X.Y.; Aghajanian, G.; Duman, R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329, 959–964. [CrossRef]
6. Autry, A.E.; Adachi, M.; Nosyreva, E.; Na, E.S.; Los, M.F.; Cheng, P.H.; Kavalali, E.T.; Monteggia, L.M. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475, 91–95. [CrossRef]
7. Monteggia, L.M.; Gideon, E.; Kavalali, E.T. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol. Psychiatry 2013, 73, 1199–1203. [CrossRef] [PubMed]
8. Nosyreva, E.; Szabla, K.; Autry, A.E.; Ryazanov, A.G.; Monteggia, L.M.; Kavalali, E.T. Acute Suppression of Spontaneous Neurotransmission Drives Synaptic Potentiation. J. Neurosci. 2013, 33, 6990–7002. [CrossRef]
9. Fogaca, M.V.; Fukumoto, K.; Franklin, T.; Liu, R.J.; Duman, C.H.; Vitolo, O.V.; Duman, R.S. N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology 2019, 44, 2230–2238. [CrossRef]
10. Grand, T.; Abi Gerges, S.; David, M.; Diana, M.A.; Paolotti, P. Unmasking GluN1/GluN3A excitatory glycine NMDA receptors. Nat. Commun. 2018, 9, 4769. [CrossRef]
11. Mealing, G.A.; Lanthorn, T.H.; Murray, C.L.; Small, D.L.; Morley, P. Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J. Pharmacol. Exp. Ther. 1999, 288, 204–210. [CrossRef]
12. Gorman, A.L.; Elliott, K.J.; Inturrisi, C.E. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci. Lett. 1997, 223, 5–8. [CrossRef]
13. Fava, M.; Stahl, S.; Pan, L.; De Martinis, S.; Pappagallo, M.; Guidetti, C.; Alimonti, A.; Bettini, E.; Mangano, R.M.; Wessel, T.; et al. REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. Am. J. Psychiatry 2013, 179, 122–131. [CrossRef]
14. Kenakin, T. Overview of receptor interactions of agonists and antagonists. Curr. Protoc. Pharmacol. 2008, 42. [CrossRef]
15. Kenakin, T.P. Biased signalling and allosteric machines: New vistas and challenges for drug discovery. Br. J. Pharmacol. 2012, 165, 1659–1669. [CrossRef]
16. Leach, K.; Sexton, P.M.; Christopoulos, A. Allosteric GPCR modulators: Taking advantage of permissive receptor pharmacology. Trends Pharmacol. Sci. 2007, 28, 382–389. [CrossRef]
17. Kuner, T.; Schoepfer, R. Multiple structural elements determine subunit specificity of Mg²⁺ block in NMDA receptor channels. J. Neurosci. 1996, 16, 3549–3558. [CrossRef]
18. Mealing, G.A.; Lanthorn, T.H.; Small, D.L.; Murray, R.J.; Mattes, K.C.; Comas, T.M.; Morley, P. Structural modifications to an N-methyl-D-aspartate receptor antagonist result in large differences in trapping block. J. Pharmacol. Exp. Ther. 2001, 297, 906–914. [CrossRef]
19. Chou, T.H.; Tajima, N.; Romero-Hernandez, A.; Furukawa, H. Structural Basis of Functional Transitions in Mammalian NMDA Receotors. Cell 2020, 182, 357–371.e13. [CrossRef]
20. Zarate, C.A., Jr.; Singh, J.B.; Carlson, P.J.; Brutsche, N.E.; Ameli, R.; Luckenbaugh, D.A.; Charney, D.S.; Manji, H.K. A randomized trial of an N-methyl-D-aspartate receptor antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63, 856–864. [CrossRef]
21. Tabuteau, H.; Jones, A.; Anderson, A.; Jacobson, M.; Iosifescu, D.V. Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: A randomized double-blind controlled trial. Am. J. Psychiatry 2022, 179, 490–499. [CrossRef]
22. Hollmann, M.; Heinemann, S. Cloned glutamate receptors. Annu. Rev. Neurosci. 1994, 17, 31–108. [CrossRef]
23. Qian, A.; Buller, A.L.; Johnson, J.W. NR2 subunit-dependence of NMDA receptor channel block by external Mg\(^{2+}\). J. Physiol. 2005, 562, 319–331. [CrossRef]

24. Kotermanski, S.E.; Johnson, J.W. Mg\(^{2+}\) imparts NMDA receptor subtype selectivity to the Alzheimer’s drug memantine. J. Neurosci. 2009, 29, 2774–2779. [CrossRef]

25. Espinosa, F.; Kavalali, E.T. NMDA receptor activation by spontaneous glutamatergic neurotransmission. J. Neurophysiol. 2009, 101, 2290–2296. [CrossRef]

26. Bürgi, H.B.; Dunütz, J.D.; Shefter, E. Pharmacological implications of the conformation of the mehdathone base. Nat. New Biol. 1973, 244, 186–187. [CrossRef]

27. Kishi, T.; Matsunaga, S.; Iwata, N. A meta-analysis of memantine for depression. J. Alzheimers Dis. 2017, 57, 113–121. [CrossRef]

28. Bifari, F.; Pappagallo, M.; Beaivins, M.; Traversa, S.; Folli, F.; Manfredi, P.L. REL-1017 (esmethadone), a novel NMDAR blocker for the treatment of MDD is not neurotoxic in Sprague-Dawley rats. Front. Pharmacol. 2022, 13, 863959. [CrossRef]

29. Morris, P.J.; Burke, R.D.; Sharma, A.K.; Lynch, D.C.; Lemke-Boucher, L.E.; Mathew, S.; Elayan, I.; Rao, D.B.; Gould, T.D.; Zaraate, C.A., Jr.; et al. A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801. Neurotoxicol. Teratol. 2021, 87, 106993. [CrossRef]

30. Olney, J.W.; Labruyere, J.; Price, M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989, 244, 1360–1362. [CrossRef]

31. Olney, J.W.; Labruyere, J.; Wang, G.; Wozniak, D.F.; Price, M.T.; Sesma, M.A. NMDA antagonist neurotoxicity: Mechanism and prevention. Science 1991, 254, 1515–1518. [CrossRef] [PubMed]

32. Wozniak, D.F.; Dikranian, K.; Ishimaru, M.J.; Nardi, A.; Corso, T.D.; Tenkova, T.; Olney, J.W.; Fix, A.S. Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: Potential relevance to Alzheimer’s disease. Neurobiol. Dis. 1998, 5, 305–322. [CrossRef] [PubMed]

33. Zhang, Y.; Ye, F.; Zhang, T.; Lv, S.; Zhou, L.; Du, D.; Lin, H.; Guo, F.; Luo, C.; Zhu, S. Structural basis of ketamine action on human NMDA receptors. Nature 2021, 596, 301–305. [CrossRef]

34. Bolshakov, K.V.; Gmiro, V.E.; Tikhonov, D.B.; Magazanik, L.G. Determinants of trapping block of N-methyl-D-aspartate receptor channels. J. Neurochem. 2003, 87, 56–65. [CrossRef]

35. De Martin, S.; Gabbia, D.; Folli, E.; Bifari, F.; Fiorina, P.; Ferri, N.; Stahl, S.; Inturrisi, C.E.; Pappagallo, M.; Traversa, S.; et al. REL-1017 (esmethadone) increases circulating BDNF levels in healthy subjects of a phase 1 clinical study. Front. Pharmacol. 2021, 12, 671859. [CrossRef]

36. Pochwat, B.; Palucha-Poniewiera, A.; Szewczyk, B.; Pilc, A.; Nowak, G. NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opin. Investig. Drugs 2014, 23, 1181–1192. [CrossRef]

37. Molero, P.; Ramos-Quiroga, J.A.; Martin-Santos, R.; Calvo-Sanchez, E.; Gutierrez-Rojas, L.; Meana, J.J. Antidepressant efficacy and tolerability of ketamine and esketamine: A critical review. CNS Drugs 2018, 32, 411–420. [CrossRef]

38. Ballard, E.D.; Zarate, C.A. The role of dissociation in ketamine’s antidepressant effects. Nat. Commun. 2020, 11, 6431. [CrossRef]

39. Bernstein, G.; Davis, K.; Mills, C.; Wang, L.; McDonnell, M.; Oldenhof, J.; Inturrisi, C.; Manfredi, P.L.; Vitolo, O.V. Characterization of the safety and pharmacokinetic profile of D-methadone, a novel N-Methyl-D-Aspartate Receptor antagonist in healthy, opioid-naive subjects: Results of two phase 1 studies. J. Clin. Psychopharmacol. 2019, 39, 226–237. [CrossRef]

40. De Martin, S.; Colognesi, M.; Inturrisi, C.E.; Mattarei, A.; Bettini, E.; Pappagallo, M.; Manfredi, P.L. Esmethadone (REL-1017) restores NMDA receptor 1 subunit expression in an in vitro model of glutamatergic excitotoxicity. Biol. Psychiatry 2021, 89, S383–S384. [CrossRef]

41. Ide, S.; Ikekubo, Y.; Mishina, M.; Hashimoto, K.; Ikeda, K. Role of NMDA receptor GluN2D subunit in the antidepressant effects of enantiomers of ketamine. J. Pharmacol. Sci. 2017, 135, 138–140. [CrossRef]

42. Dingedline, R.; Borges, K.; Bowie, D.; Traynelis, S.F. The glutamate receptor ion channels. Pharmacol. Rev. 1999, 51, 7–61.

43. Bettini, E.; Sava, A.; Griffante, C.; Carignani, C.; Buson, A.; Capelli, A.M.; Negri, M.; Andreetta, F.; Senar-Sancho, S.A.; Guiral, L.; et al. Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors. J. Pharmacol. Exp. Ther. 2010, 335, 636–644. [CrossRef]

44. Cheng, Y.; Prusoff, W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099–3108. [CrossRef]

45. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739–1749. [CrossRef]

46. Friesner, R.A.; Murphy, R.B.; Repasky, M.P.; Frye, L.L.; Greenwood, J.R.; Halgren, T.A.; Sanschagrin, P.C.; Mainz, D.T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 2006, 49, 6177–6196. [CrossRef]